RAAS inhibition and beyond—cardiovascular medications in patients at risk of or affected by COVID-19

Alexander Dutsch; Heribert Schunkert

doi:10.1007/s00059-023-05168-4

RAAS inhibition and beyond—cardiovascular medications in patients at risk of or affected by COVID-19

Alexander Dutsch, Heribert Schunkert

Clinic for Heart and Vascular Diseases

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

The COVID-19 pandemic led to an enormous burden on healthcare systems worldwide. Causal therapy is still in its infancy. Contrary to initial views that the use of angiotensin-converting enzyme inhibitors (ACEi)/angiotensin II receptor blockers (ARBs) may increase the risk for a deleterious disease course, it has been shown that these agents may actually be beneficial for patients affected by COVID-19. In this article, we provide an overview of the three most commonly used classes of drugs in cardiovascular disease (ACEi/ARB, statins, beta-blockers) and their potential role in COVID-19 therapy. More results from randomized clinical trials are necessary to identify patients that can benefit most from the use of the respective drugs.

Translated title of the contribution	RAAS-Hemmung und darüber hinaus – Herz-Kreislauf-Medikation bei Patienten mit einem Risiko für oder Erkrankung durch COVID-19
Original language	English
Pages (from-to)	206-211
Number of pages	6
Journal	Herz
Volume	48
Issue number	3
DOIs	https://doi.org/10.1007/s00059-023-05168-4
State	Published - Jun 2023

Keywords

Beta-blockers
Cardiovascular disease
Renin–angiotensin–aldosterone inhibition
SARS-CoV‑2
Statins

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00059-023-05168-4

Cite this

@article{3491e095a862462ebd4739d8da77e8fb,

title = "RAAS inhibition and beyond—cardiovascular medications in patients at risk of or affected by COVID-19",

abstract = "The COVID-19 pandemic led to an enormous burden on healthcare systems worldwide. Causal therapy is still in its infancy. Contrary to initial views that the use of angiotensin-converting enzyme inhibitors (ACEi)/angiotensin II receptor blockers (ARBs) may increase the risk for a deleterious disease course, it has been shown that these agents may actually be beneficial for patients affected by COVID-19. In this article, we provide an overview of the three most commonly used classes of drugs in cardiovascular disease (ACEi/ARB, statins, beta-blockers) and their potential role in COVID-19 therapy. More results from randomized clinical trials are necessary to identify patients that can benefit most from the use of the respective drugs.",

keywords = "Beta-blockers, Cardiovascular disease, Renin–angiotensin–aldosterone inhibition, SARS-CoV‑2, Statins",

author = "Alexander Dutsch and Heribert Schunkert",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.",

year = "2023",

month = jun,

doi = "10.1007/s00059-023-05168-4",

language = "English",

volume = "48",

pages = "206--211",

journal = "Herz",

issn = "0340-9937",

publisher = "Springer Medizin",

number = "3",

}

TY - JOUR

T1 - RAAS inhibition and beyond—cardiovascular medications in patients at risk of or affected by COVID-19

AU - Dutsch, Alexander

AU - Schunkert, Heribert

PY - 2023/6

Y1 - 2023/6

N2 - The COVID-19 pandemic led to an enormous burden on healthcare systems worldwide. Causal therapy is still in its infancy. Contrary to initial views that the use of angiotensin-converting enzyme inhibitors (ACEi)/angiotensin II receptor blockers (ARBs) may increase the risk for a deleterious disease course, it has been shown that these agents may actually be beneficial for patients affected by COVID-19. In this article, we provide an overview of the three most commonly used classes of drugs in cardiovascular disease (ACEi/ARB, statins, beta-blockers) and their potential role in COVID-19 therapy. More results from randomized clinical trials are necessary to identify patients that can benefit most from the use of the respective drugs.

AB - The COVID-19 pandemic led to an enormous burden on healthcare systems worldwide. Causal therapy is still in its infancy. Contrary to initial views that the use of angiotensin-converting enzyme inhibitors (ACEi)/angiotensin II receptor blockers (ARBs) may increase the risk for a deleterious disease course, it has been shown that these agents may actually be beneficial for patients affected by COVID-19. In this article, we provide an overview of the three most commonly used classes of drugs in cardiovascular disease (ACEi/ARB, statins, beta-blockers) and their potential role in COVID-19 therapy. More results from randomized clinical trials are necessary to identify patients that can benefit most from the use of the respective drugs.

KW - Beta-blockers

KW - Cardiovascular disease

KW - Renin–angiotensin–aldosterone inhibition

KW - SARS-CoV‑2

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=85153604476&partnerID=8YFLogxK

U2 - 10.1007/s00059-023-05168-4

DO - 10.1007/s00059-023-05168-4

M3 - Article

C2 - 37097476

AN - SCOPUS:85153604476

SN - 0340-9937

VL - 48

SP - 206

EP - 211

JO - Herz

JF - Herz

IS - 3

ER -

RAAS inhibition and beyond—cardiovascular medications in patients at risk of or affected by COVID-19

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this